Skip to main content
. 2021 Jun 16;13(6):1152. doi: 10.3390/v13061152

Table 2.

Clinicopathological characteristics and laboratory findings of patients in the study cohort 1.

Patients Positive for Each DENV Serotype (N, %)
Patient Characteristic DENV-1
(n = 64, 30.1%)
DENV-2
(n = 8, 3.8%)
DENV-3
(n = 98, 46.2%)
DENV-4
(n = 42, 19.8%)
Total
(n = 212, 100%)
p Value
Age (years) 8.8 (±5.1) 2 8.0 (±4.6) 9.6 (±5.4) 11.7 (±5.4) 9.7 (±6.3)
Age group (years)
≤12 52 (32.5%) 7 (4.4%) 75 (46.8%) 26 (16.3%) 160 (100%) 0.111
>12 12 (23%) 1 (2%) 23 (44.2%) 16 (30.8) 52 (100%)
Gender
Male 30 (46.8%) 6 (75%) 64 (65.3%) 20 (47.6%) 120 (56.7%) 0.047
Female 34 (53.2%) 2 (25%) 34 (34.7%) 22 (52.4%) 92 (43.3%)
Signs and Symptoms
Rash 3 0 8 3 14 0.717
Hess test 62 7 94 38 201 0.038
Coffee ground vomiting 4 1 13 1 19 0.161
Muscle pain 6 1 19 12 38 0.081
Joint pain 6 1 17 10 34 0.241
Abdominal pain 21 2 31 15 69 0.932
Hepatomegaly 41 5 39 20 105 0.027
Splenomegaly 0 0 1 1 2 0.632
Drowsiness 17 2 31 8 58 0.493
Thrombocytopenia.
(<150,000/μL platelets)
26 2 32 20 80 0.308
Epistaxis 11 2 19 5 37 0.689
Melena 0 0 7 1 8 0.106
Symptoms 3
Without warning signs 27 (42.2%) 2 (25%) 27 (27.5%) 18 (42.8%) 74 (34.9%)
With warning signs 32 (50%) 6 (75%) 62 (63.3%) 19 (45.2%) 119 (56.1%) 0.284
Severe dengue 5 (7.8%) 0 9 (9.2%) 5 (12%) 19 (9%)
Anti-DENV IgM 4
Negative 24 (37.5%) 3 (37.5%) 43 (43.8%) 12 (28.6%) 82 (38.7%) 0.397
Positive 40 (62.5%) 5 (62.5%) 55 (56.2%) 30 (71.4%) 130 (61.3%)
Type of infection 5
Primary 31 (48.4%) 1 (12.5%) 50 (51%) 5 (11.9%) 87 (41%) <0.001
Secondary 33 (51.6%) 7 (87.5%) 48 (49%) 37 (88.1%) 125 (59%)

1 Patients was confirmed positive by virus isolation, 2 Mean ± standard deviation, 3 WHO classification system, 4 as determined by capture ELISA, 5 as determined by in-house dengue IgG indirect ELISA, underline indicates statistically significant values (p value < 0.05).